Record Information |
---|
Version | 1.0 |
---|
Creation Date | 2009-07-21 20:27:40 UTC |
---|
Update Date | 2016-11-09 01:08:43 UTC |
---|
Accession Number | CHEM002275 |
---|
Identification |
---|
Common Name | Alfentanil |
---|
Class | Small Molecule |
---|
Description | A short-acting opioid anesthetic and analgesic derivative of fentanyl. It produces an early peak analgesic effect and fast recovery of consciousness. Alfentanil is effective as an anesthetic during surgery, for supplementation of analgesia during surgical procedures, and as an analgesic for critically ill patients. [PubChem] |
---|
Contaminant Sources | - HMDB Contaminants - Urine
- STOFF IDENT Compounds
- T3DB toxins
|
---|
Contaminant Type | - Amide
- Amine
- Analgesic
- Analgesic, Opioid
- Anesthetic
- Anesthetic, Intravenous
- Drug
- Ether
- Metabolite
- Narcotic
- Opiate Agonist
- Organic Compound
- Synthetic Compound
|
---|
Chemical Structure | |
---|
Synonyms | Value | Source |
---|
Alfentanilum | ChEBI | Alfentanyl | ChEBI | N-(1-(2-(4-Ethyl-5-oxo-2-tetrazolin-1-yl)ethyl)-4-(methoxymethyl)-4-piperidyl)propionanilide | ChEBI | Rapifen | Kegg | Esteve brand OF alfentanil hydrochloride | HMDB | Fanaxal | HMDB | ICI brand OF alfentanil hydrochloride | HMDB | Janssen brand OF alfentanil hydrochloride | HMDB | Limifen | HMDB | Alfenta | HMDB | Alfentanil hydrochloride | HMDB |
|
---|
Chemical Formula | C21H32N6O3 |
---|
Average Molecular Mass | 416.517 g/mol |
---|
Monoisotopic Mass | 416.254 g/mol |
---|
CAS Registry Number | 71195-58-9 |
---|
IUPAC Name | N-{1-[2-(4-ethyl-5-oxo-4,5-dihydro-1H-1,2,3,4-tetrazol-1-yl)ethyl]-4-(methoxymethyl)piperidin-4-yl}-N-phenylpropanamide |
---|
Traditional Name | alfentanil |
---|
SMILES | CCN1N=NN(CCN2CCC(COC)(CC2)N(C(=O)CC)C2=CC=CC=C2)C1=O |
---|
InChI Identifier | InChI=1S/C21H32N6O3/c1-4-19(28)27(18-9-7-6-8-10-18)21(17-30-3)11-13-24(14-12-21)15-16-26-20(29)25(5-2)22-23-26/h6-10H,4-5,11-17H2,1-3H3 |
---|
InChI Key | IDBPHNDTYPBSNI-UHFFFAOYSA-N |
---|
Chemical Taxonomy |
---|
Description | belongs to the class of organic compounds known as anilides. These are organic heterocyclic compounds derived from oxoacids RkE(=O)l(OH)m (l not 0) by replacing an OH group by the NHPh group or derivative formed by ring substitution. |
---|
Kingdom | Organic compounds |
---|
Super Class | Benzenoids |
---|
Class | Benzene and substituted derivatives |
---|
Sub Class | Anilides |
---|
Direct Parent | Anilides |
---|
Alternative Parents | |
---|
Substituents | - Anilide
- Piperidine
- Azole
- Heteroaromatic compound
- Tertiary carboxylic acid amide
- Tetrazole
- Amino acid or derivatives
- Carboxamide group
- Tertiary amine
- Tertiary aliphatic amine
- Carboxylic acid derivative
- Dialkyl ether
- Ether
- Azacycle
- Organoheterocyclic compound
- Organonitrogen compound
- Organic nitrogen compound
- Amine
- Organopnictogen compound
- Organooxygen compound
- Organic oxide
- Hydrocarbon derivative
- Organic oxygen compound
- Carbonyl group
- Aromatic heteromonocyclic compound
|
---|
Molecular Framework | Aromatic heteromonocyclic compounds |
---|
External Descriptors | |
---|
Biological Properties |
---|
Status | Detected and Not Quantified |
---|
Origin | Exogenous |
---|
Cellular Locations | |
---|
Biofluid Locations | Not Available |
---|
Tissue Locations | Not Available |
---|
Pathways | Not Available |
---|
Applications | |
---|
Biological Roles | |
---|
Chemical Roles | Not Available |
---|
Physical Properties |
---|
State | Solid |
---|
Appearance | White powder. |
---|
Experimental Properties | Property | Value |
---|
Melting Point | 140.8°C | Boiling Point | Not Available | Solubility | 34.6 mg/L |
|
---|
Predicted Properties | |
---|
Spectra |
---|
Spectra | Spectrum Type | Description | Splash Key | View |
---|
Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | splash10-0aps-5759000000-11ce8f647981a86e2993 | Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | Spectrum | Predicted GC-MS | Predicted GC-MS Spectrum - GC-MS (Non-derivatized) - 70eV, Positive | Not Available | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QTOF , positive | splash10-014i-0000900000-a802cc961dad7c6326a5 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QTOF , positive | splash10-014i-0395300000-498fafc6962b6fd82e9c | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QTOF , positive | splash10-00kb-0912000000-43c2343a5fa4997ca93a | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QTOF , positive | splash10-015a-2900000000-16b845b2c742175e38cd | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - LC-ESI-QTOF , positive | splash10-015a-7900000000-e9bd243460dd40507619 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 40V, Positive | splash10-015a-2900000000-16b845b2c742175e38cd | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 50V, Positive | splash10-015a-7900000000-e9bd243460dd40507619 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 30V, Positive | splash10-00kb-0912000000-43c2343a5fa4997ca93a | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 30V, Positive | splash10-00kb-0912000000-b5e89d86b302adb65517 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 40V, Positive | splash10-015a-2900000000-d76f968c16c60e097fbc | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 20V, Positive | splash10-014i-0395300000-498fafc6962b6fd82e9c | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 10V, Positive | splash10-014i-0000900000-a802cc961dad7c6326a5 | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 50V, Positive | splash10-015a-7900000000-7fdf62ef447e7c6e19fa | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 30V, Positive | splash10-00kb-0912000000-1f6c2333f39ce390e20e | Spectrum | LC-MS/MS | LC-MS/MS Spectrum - 50V, Positive | splash10-015a-7900000000-1c558c3f776664f15eb1 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-00di-9007000000-cbc10f94b61327a4ec79 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-0006-9022000000-5dee7e8e9ca18ed6afa7 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0006-9052000000-d1f0fa6385e6848912c6 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-0cdr-6509300000-1d06eb64c3c9a376ea43 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Negative | splash10-0a4i-3109000000-3960d2bbff65d1a0ecc0 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Negative | splash10-0btc-9423000000-8194ccf6d27ec2cb2870 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Positive | splash10-014i-0000900000-1e0b9eadc3dc511d87d7 | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 20V, Positive | splash10-014i-0392100000-333cd54e08c49ae75cde | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 40V, Positive | splash10-0296-1936000000-2f1acf618b9904cbaffe | Spectrum | Predicted LC-MS/MS | Predicted LC-MS/MS Spectrum - 10V, Negative | splash10-014i-0009300000-f5e9f9e4f40759f2ff43 | Spectrum |
|
---|
Toxicity Profile |
---|
Route of Exposure | For intravenous injection or infusion only. |
---|
Mechanism of Toxicity | Opiate receptors are coupled with G-protein receptors and function as both positive and negative regulators of synaptic transmission via G-proteins that activate effector proteins. Binding of the opiate stimulates the exchange of GTP for GDP on the G-protein complex. As the effector system is adenylate cyclase and cAMP located at the inner surface of the plasma membrane, opioids decrease intracellular cAMP by inhibiting adenylate cyclase. Subsequently, the release of nociceptive neurotransmitters such as substance P, GABA, dopamine, acetylcholine and noradrenaline is inhibited. Opioids also inhibit the release of vasopressin, somatostatin, insulin and glucagon. Alfentanil's analgesic activity is, most likely, due to its conversion to morphine. Opioids close N-type voltage-operated calcium channels (OP2-receptor agonist) and open calcium-dependent inwardly rectifying potassium channels (OP3 and OP1 receptor agonist). This results in hyperpolarization and reduced neuronal excitability. |
---|
Metabolism | The liver is the major site of biotransformation.
Route of Elimination: Only 1.0% of the dose is excreted as unchanged drug; urinary excretion is the major route of elimination of metabolites.
Half Life: 90-111 minutes |
---|
Toxicity Values | Not Available |
---|
Lethal Dose | Not Available |
---|
Carcinogenicity (IARC Classification) | No indication of carcinogenicity to humans (not listed by IARC). |
---|
Uses/Sources | For the management of postoperative pain and the maintenance of general anesthesia. |
---|
Minimum Risk Level | Not Available |
---|
Health Effects | Medical problems can include congested lungs, liver disease, tetanus, infection of the heart valves, skin abscesses, anemia and pneumonia. Death can occur from overdose. |
---|
Symptoms | Symptoms of overexposure include characteristic rigidity of the skeletal muscles, cardiac and respiratory depression, and narrowing of the pupils. |
---|
Treatment | Intravenous administration of an opioid antagonist such as naloxone should be employed as a specific antidote to manage respiratory depression. The duration of respiratory depression following overdosage with ALFENTA may be longer than the duration of action of the opioid antagonist. Administration of an opioid antagonist should not preclude immediate establishment of a patent airway, administration of oxygen, and assisted or controlled ventilation as indicated for hypoventilation or apnea. If respiratory depression is associated with muscular rigidity, a neuromuscular blocking agent may be required to facilitate assisted or controlled ventilation. Intravenous fluids and vasoactive agents may be required to manage hemodynamic instability. (2) |
---|
Concentrations |
---|
| Not Available |
---|
External Links |
---|
DrugBank ID | DB00802 |
---|
HMDB ID | HMDB0014940 |
---|
FooDB ID | Not Available |
---|
Phenol Explorer ID | Not Available |
---|
KNApSAcK ID | Not Available |
---|
BiGG ID | Not Available |
---|
BioCyc ID | Not Available |
---|
METLIN ID | Not Available |
---|
PDB ID | Not Available |
---|
Wikipedia Link | Alfentanil |
---|
Chemspider ID | 46451 |
---|
ChEBI ID | 2569 |
---|
PubChem Compound ID | 51263 |
---|
Kegg Compound ID | C08005 |
---|
YMDB ID | Not Available |
---|
ECMDB ID | Not Available |
---|
References |
---|
Synthesis Reference | Jacob Mathew, J. Killgore, “New methods for the synthesis of alfentanil, sufentanil, and remifentanil.” U.S. Patent US20060149071, issued July 06, 2006. |
---|
MSDS | Link |
---|
General References | |
---|